China’s New Legal Power To Limit Or Block Mergers Could Signal Challenges For Global Pharmaceutical Alliances
This article was originally published in The Pink Sheet Daily
Executive Summary
Armed with a new antitrust law, the Ministry of Commerce could derail megamergers of companies with an interest in China, like Pfizer/Wyeth, slated to be completed later this year.